SPRB — SPRUCE BIOSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1683553 ·
Last close
$42.83
Market Cap
$117.88M
52W High
$60.27
52W Low
$40.33
ADV30
79,740
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -11,987,000 | -12,266,000 | 56,166,000 | 54,080,000 | 21,518,000 |
| Dec 2025 | 0 | — | -11,100,000 | -14,646,000 | 53,021,000 | 48,906,000 | 10,505,000 |
| Sep 2025 | 0 | — | -8,229,000 | -8,212,000 | 15,313,000 | 10,669,000 | 9,927,000 |
| Jun 2025 | 0 | — | -2,692,000 | -2,067,000 | 21,820,000 | 16,387,000 | 8,640,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-29,332,000
Investing CF
$-10,000
Financing CF
$57,808,000
CapEx
$-10,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-50.96
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-301,500,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-36,463,000
Pretax Income TTM
$-37,191,000
Interest Exp TTM
$728,000
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -36,513,000 | -38,966,000 | 53,021,000 | 10,505,000 | — | -33,327,000 |
| Dec 2024 | 4,911,000 | -56,151,000 | -53,036,000 | 45,209,000 | 16,388,000 | — | -55,964,000 |
| Dec 2023 | 10,089,000 | -51,993,000 | -47,919,000 | 103,946,000 | 27,437,000 | — | -33,275,000 |
| Dec 2022 | 0 | -47,283,000 | -46,180,000 | 85,648,000 | 17,162,000 | — | -41,683,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$7.38
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANIX | Anixa Biosciences Inc | $116.36M | $3.42 | — |
| PEPG | PepGen Inc. | $121.74M | $1.76 | — |
| PMN | ProMIS Neurosciences Inc. | $123.04M | $13.72 | — |
| CUE | Cue Biopharma, Inc. | $112.74M | $26.84 | — |
| PLYX | Polaryx Therapeutics, Inc. | $109.36M | $2.31 | — |
News headlines (Yahoo Finance, 1h cache)
Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
2026-07-27 12:00 · Yahoo
American Express, Biogen upgraded: Wall Street's top analyst calls
2026-07-13 13:41 · Yahoo
Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit
2026-07-08 20:01 · Yahoo
Here Are Tuesday’s Best Wall Street Analyst Research Calls: Dynatrace, Emerson Electric, Exxon Mobil, Flutter Entertainment, Genuine Parts, nVent Electric, Palantir Technologies, Roku, and More
2026-06-16 11:52 · Yahoo
Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls
2026-06-09 13:32 · Yahoo
Wall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to Trade
2026-04-03 13:55 · Yahoo
Does Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?
2026-03-18 13:55 · Yahoo
Spruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net Loss
2026-03-17 23:59 · Yahoo
Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway
2026-03-04 05:11 · Yahoo
Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference
2026-03-01 22:37 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.